Skip to main content
. 2020 Nov 6;112(1):305–313. doi: 10.1111/cas.14681

FIGURE 2.

FIGURE 2

Best percent change in sum of target lesion diameters from baseline per independent review committee in efficacy‐evaluable patients with programmed death ligand 1‐positive urothelial carcinoma